Abbvie Inc. · NYSE:ABBV
Abbvie — J.P. Morgan Healthcare Conference 2016
16 slides from Abbvie's conference presentation, Jan 13, 2016
Slide 1: J.P. Morgan Healthcare Conference
J.P. MORGAN HEALTHCARE CONFERENCE Richard Gonzalez Chairman and Chief Executive Officer January 13, 2016
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, gen
Slide 3: AbbVie Mission
AbbVie Mission Create an innovation-driven, patient-focused, specialty biopharmaceutical company capable of achieving top-tier performance through outstanding execution and a consistent stream of innovative new medicines J.P. Morgan Healthcare Conference | January 13, 2016 |© 2016 3
Slide 4: AbbVie Represents a Unique Investment Opportunity
AbbVie Represents a Unique Investment Opportunity Compelling capital Industry-leading growth, Impressive pipeline of allocation philosophy, supported by a portfolio mid- and late-stage assets balanced between of leading brands in that have been de-risked supporting growth attractive and sustainable
Slide 5: Sustainable Leadership Positions in Specialty Markets
Sustainable Leadership Positions in Specialty Markets Immunology Oncology Virology Market $47BN >$85BN $23BN AbbVie • Clear leadership positions in: Rheum, • Flagship product in hematologic • Established foothold with Position Gastro and Derm oncology with first-in-class BTK- Viekira inhibitor, Imbr
Slide 6: Immunology: Comprehensive Strategy to Maintain Leadership in a $47BN Market
Immunology: Comprehensive Strategy to Maintain Leadership in a $47BN Market 1 Strong Commercial Execution 2 Further Enhancements to Humira 3 Intellectual Property 4 Strong Immunology Pipeline HUMIRA Sales ($BN) Robust Pipeline of Mid- and Late- >18 Stage Assets with Potential for Significant Differe
Slide 7: Oncology: Establishing Leadership in Treatment of Blood Cancers
Oncology: Establishing Leadership in Treatment of Blood Cancers Advancing Our Hematologic Oncology Pipeline Current Indications Pipeline Indications Imbruvica • CLL (R/R) • First-line CLL alone and in combination Significant Data • First-line line CLL (del 17p) with anti-CD20 • Waldenstrom • DLBCL (
Slide 8: Oncology: Establishing Leadership in Treatment of Blood Cancers
Oncology: Establishing Leadership in Treatment of Blood Cancers NEJM: Imbruvica Front-Line CLL Data (RESONATE-2) $7BN+ Peak-Sales Potential for AbbVie • 91% reduction in risk of progression or death with ibrutinib • 18-month PFS rate: 94% with ibrutinib vs. 45% with chlorambucil • PFS results consis
Slide 9: Numerous De-Risked Late-Stage Programs
Numerous De-Risked Late-Stage Programs Total Pipeline Has Potential to Deliver Nearly $30BN in Nominal New Revenue by 2024 Immunology Oncology Virology Neurology Other Phase 3 Submitted Phase 3 Submitted Phase 3 • JAK1: ABT-494 • Bcl2: Venetoclax • Highly competitive • Zinbryta • Elagolix next-gen r
Slide 10: Multiple Pipeline Catalysts in 2016
Multiple Pipeline Catalysts in 2016 2016 Regulatory Submissions & Approvals Key 2016 Data Readouts • Imbruvica: Label update in R/R CLL in combination • Imbruvica: Potential for data in MCL, DLBCL, FL or with B/R (HELIOS); expansion into 1st-line CLL and MZL; timing dependent on event driven (RESONA
Slide 11: Outstanding Track Record of Execution
Outstanding Track Record of Execution $5.50 +17.1% 5.00 $5.00 $4.50 +28.6% 4.27 4.15 EPS* $4.00 +5.7% $3.50 3.32 3.08 3.14 3.05 $3.00 $2.50 Initial Actual Initial Actual Initial Guidance Guidance Guidance Guidance Guidance Mid-Point Mid-Point 2013 2014 2015 2016 Forecasting double-digit adjusted EPS
Slide 12: A Commitment to Operating Margin Expansion While Investing For the Future
A Commitment to Operating Margin Expansion While Investing For the Future + 710 bps + 1,120 bps $850MM Gross Margin Operating Margin R&D as a % of Sales as a % of Sales Increase in Annual Investment Q3 2015 vs. Q1 2013 Since 2012 Note: Adjusted for one-time items J.P. Morgan Healthcare Conference |
Slide 13: Recently Announced Long-Term Projections Represent Top-Tier Growth Prospects
Recently Announced Long-Term Projections Represent Top-Tier Growth Prospects ~$37BN • Potential for >20 new >50% drugs or indications by 2020 36% • Expect pipeline to $19.9BN add more than $4BN in risk-adjusted sales in 2020* • Top-tier revenue and EPS growth * Excluding new Humira and Imbruvica ind
Slide 14: AbbVie Offers Both Compelling Growth and Strong Capital Allocation
AbbVie Offers Both Compelling Growth and Strong Capital Allocation • Track record of strong and growing dividend; increasing 2016 dividend by 12 percent, beginning with dividend payable in February 2016 • AbbVie repurchased significant shares in 2015 Dividend Increases $0.80 Reflects Increase of $0.
Slide 15: AbbVie: A Unique Investment Opportunity
AbbVie: A Unique Investment Opportunity Sustainable leadership in specialty markets with leading brands De-risked, late-stage pipeline Attractive return of capital History of strong execution A unique investment vehicle, offering top-tier revenue and EPS growth, significant cash flow and strong retu
Slide 16: Qobvie
Qobvie